Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.
J Am Acad Dermatol
; 69(5): 708-720, 2013 Nov.
Article
em En
| MEDLINE
| ID: mdl-23981682
ABSTRACT
BACKGROUND:
Pruritus has been anecdotally described in association with targeted cancer therapies. The risk of pruritus has not been systematically ascertained.OBJECTIVE:
A systematic review and meta-analysis of the literature was conducted for axitinib, cetuximab, dasatinib, erlotinib, everolimus, gefitinib, imatinib, ipilimumab, lapatinib, nilotinib, panitumumab, pazopanib, rituximab, sorafenib, temsirolimus, tositumomab, vandetanib, and vemurafenib.METHODS:
Databases from PubMed, Web of Science (January 1998 through July 2012), and American Society of Clinical Oncology abstracts (2004 through 2012) were searched. Incidence and relative risk of pruritus were calculated using random- or fixed-effects model.RESULTS:
The incidences of all-grade and high-grade pruritus were 17.4% (95% confidence interval 16.0%-19.0%) and 1.4% (95% confidence interval 1.2%-1.6%), respectively. There was an increased risk of all-grade pruritus (relative risk 2.90 [95% confidence interval 1.76-4.77, P < .001]) and variation among different drugs (P < .001).LIMITATIONS:
The reporting of pruritus may vary, resulting from concomitant medications, comorbidities, and underlying malignancies. We found a higher incidence of pruritus in patients with solid tumors, concordant with those targeted therapies with the highest pruritus incidences.CONCLUSION:
There is a significant risk of developing pruritus in patients receiving targeted therapies. To prevent suboptimal dosing and decreased quality of life, patients should be counseled and treated against this untoward symptom.Palavras-chave
AE; B-lymphocyte antigen cluster of differentiation 20; Bcr-Abl; CD20; CI; CTLA4; EGFR; EGFRIs; HER2; QoL; RR; Raf; T-lymphocyte antigen 4; VEGFR; adverse events; cancer; confidence interval; epidermal growth factor receptor; epidermal growth factor receptor inhibitors; human epidermal growth factor receptor 2; inhibitor; itch; mammalian target of rapamycin; pruritus; quality of life; relative risk; vascular endothelial growth factor receptor
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Prurido
/
Toxidermias
/
Terapia de Alvo Molecular
/
Neoplasias
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
/
Systematic_reviews
Aspecto:
Patient_preference
Limite:
Humans
Idioma:
En
Revista:
J Am Acad Dermatol
Ano de publicação:
2013
Tipo de documento:
Article